EP Wealth Advisors LLC Sells 366 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

EP Wealth Advisors LLC trimmed its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 24.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,133 shares of the biotechnology company's stock after selling 366 shares during the period. EP Wealth Advisors LLC's holdings in Axon Enterprise were worth $673,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in AXON. Principal Financial Group Inc. grew its stake in Axon Enterprise by 33.1% in the third quarter. Principal Financial Group Inc. now owns 136,302 shares of the biotechnology company's stock worth $54,466,000 after purchasing an additional 33,869 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Axon Enterprise by 1.5% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 12,607 shares of the biotechnology company's stock valued at $7,493,000 after buying an additional 185 shares during the last quarter. HBW Advisory Services LLC bought a new stake in shares of Axon Enterprise during the fourth quarter valued at approximately $295,000. Graypoint LLC bought a new stake in shares of Axon Enterprise during the fourth quarter valued at approximately $258,000. Finally, Czech National Bank raised its holdings in Axon Enterprise by 7.4% during the fourth quarter. Czech National Bank now owns 15,707 shares of the biotechnology company's stock worth $9,335,000 after purchasing an additional 1,082 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have issued reports on AXON. JMP Securities restated an "outperform" rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. Barclays lifted their price objective on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. Northcoast Research cut shares of Axon Enterprise from a "buy" rating to a "neutral" rating in a report on Wednesday, February 19th. The Goldman Sachs Group lifted their price objective on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, Needham & Company LLC lifted their price objective on shares of Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $652.73.

Insiders Place Their Bets

In related news, CEO Patrick W. Smith sold 10,000 shares of the company's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $540.99, for a total transaction of $5,409,900.00. Following the completion of the transaction, the chief executive officer now directly owns 3,063,982 shares in the company, valued at $1,657,583,622.18. This represents a 0.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Matthew R. Mcbrady sold 400 shares of the company's stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $718.40, for a total transaction of $287,360.00. Following the transaction, the director now owns 3,492 shares of the company's stock, valued at approximately $2,508,652.80. This represents a 10.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 23,764 shares of company stock worth $14,856,635 over the last three months. Insiders own 4.40% of the company's stock.

Axon Enterprise Stock Performance

Shares of AXON traded down $0.14 during midday trading on Thursday, reaching $728.39. The stock had a trading volume of 567,282 shares, compared to its average volume of 762,145. The firm has a 50 day simple moving average of $576.22 and a 200-day simple moving average of $589.48. Axon Enterprise, Inc. has a one year low of $273.52 and a one year high of $732.22. The firm has a market cap of $56.71 billion, a PE ratio of 188.21, a P/E/G ratio of 5.17 and a beta of 1.24. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.34 by $0.07. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The business had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. During the same quarter in the previous year, the firm posted $1.15 EPS. Axon Enterprise's revenue was up 31.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Axon Enterprise, Inc. will post 5.8 EPS for the current year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.